Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling

Add-on activity                                                                                                     

This activity includes an article and patient counseling videos as part of a resource center titled “Understanding the Significant Burden of RSV Infection in Older Adults: A Comprehensive Curriculum Focused on the Role of the Pharmacist.”

Program Description

Each year in the United States, almost 170,000 older adults are hospitalized due to respiratory syncytial virus (RSV) infection and resulting complications. The manifestations of RSV increase in severity with increasing patient age. As there are currently no FDA-approved treatments for RSV, efforts to prevent RSV-associated morbidity and mortality among older adults have focused on the development of several vaccine technologies with differing mechanisms of action. This webinar will detail the latest safety and immunogenicity of emerging vaccines for RSV that are targeted for the older adult population and will feature patient counseling videos that highlight scenarios showing interactions and opportunities for pharmacists to share education about the burden of RSV and benefits of vaccination. The discussion will include strategies pharmacists can implement to minimize the spread of vaccine misinformation, overcome barriers to vaccination, and ensure higher vaccination rates among older adults at risk for RSV infection.

Target audience: Retail pharmacists

Type of activity: Application
Release date: June 8, 2023
Expiration date: August 8, 2023

Time to complete activity: 1 hour
Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Demonstrate knowledge about the incidence of severe respiratory syncytial virus (RSV) in older adults and the need for prophylactic vaccines to reduce morbidity and mortality rates
• Compare the role of recent FDA-approved Breakthrough Therapy Designated vaccines and emerging vaccines, mechanisms of action, administration, and patient education
• Express the importance of pharmacists in creating awareness about potential risk factors for severe RSV in older adults and providing patient education regarding recent FDA-approved Breakthrough Therapy Designated vaccines and emerging vaccines

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-067-L01-P. The activity is available for CE credit through August 8, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Adam C. Welch, PharmD, MBA, FAPhA

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms